Loading…

Inhibition of iNKT Cells by the HLA-G-ILT2 Checkpoint and Poor Stimulation by HLA-G-Expressing Tolerogenic DC

Invariant Natural Killer T (iNKT) cells are a small and distinct population of T cells crucial in immunomodulation. After activation by alpha-GalactosylCeramide (αGC), an exogenic glycolipid antigen, iNKT cells can rapidly release cytokines to enhance specific anti-tumor activity. Several human clin...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in immunology 2021-01, Vol.11, p.608614-608614
Main Authors: Wu, Ching-Lien, Caumartin, Julien, Amodio, Giada, Anna, François, Loustau, Maria, Gregori, Silvia, Langlade-Demoyen, Pierre, LeMaoult, Joel
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c465t-24820107460f9cd30e0185967861a507dc3b92a33eafbd3a2409b739ba893a7e3
cites cdi_FETCH-LOGICAL-c465t-24820107460f9cd30e0185967861a507dc3b92a33eafbd3a2409b739ba893a7e3
container_end_page 608614
container_issue
container_start_page 608614
container_title Frontiers in immunology
container_volume 11
creator Wu, Ching-Lien
Caumartin, Julien
Amodio, Giada
Anna, François
Loustau, Maria
Gregori, Silvia
Langlade-Demoyen, Pierre
LeMaoult, Joel
description Invariant Natural Killer T (iNKT) cells are a small and distinct population of T cells crucial in immunomodulation. After activation by alpha-GalactosylCeramide (αGC), an exogenic glycolipid antigen, iNKT cells can rapidly release cytokines to enhance specific anti-tumor activity. Several human clinical trials on iNKT cell-based anti-cancer are ongoing, however results are not as striking as in murine models. Given that iNKT-based immunotherapies are dependent mainly on antigen-presenting cells (APC), a human tolerogenic molecule with no murine homolog, such as Human Leucocyte Antigen G (HLA-G), could contribute to this discrepancy. HLA-G is a well-known immune checkpoint molecule involved in fetal-maternal tolerance and in tumor immune escape. HLA-G exerts its immunomodulatory functions through the interaction with immune inhibitory receptors such as ILT2, differentially expressed on immune cell subsets. We hypothesized that HLA-G might inhibit iNKT function directly or by inducing tolerogenic APC leading to iNKT cell anergy, which could impact the results of current clinical trials. Using an ILT2-transduced murine iNKT cell line and human iNKT cells, we demonstrate that iNKT cells are sensitive to HLA-G, which inhibits their cytokine secretion. Furthermore, human HLA-G dendritic cells, called DC-10, failed at inducing iNKT cell activation compared to their autologous HLA-G DCs counterparts. Our data show for the first time that the HLA-G/ILT2 ICP is involved in iNKT cell function modulation.
doi_str_mv 10.3389/fimmu.2020.608614
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_568a36708bcb4a4696a8741fc21f766b</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_568a36708bcb4a4696a8741fc21f766b</doaj_id><sourcerecordid>2482664223</sourcerecordid><originalsourceid>FETCH-LOGICAL-c465t-24820107460f9cd30e0185967861a507dc3b92a33eafbd3a2409b739ba893a7e3</originalsourceid><addsrcrecordid>eNpVkVFvFCEUhYnR2Kb2B_hiePRlVobLwPBi0oy13bhRE9dnAgyzS50ZVpgx9t_L7tSm5QFu4JwDlw-htyVZAdTyQ-eHYV5RQsmKk5qX7AU6LzlnBVDKXj6pz9BlSnckDyYBoHqNzvJMKpDiHA3rce-Nn3wYceiw__plixvX9wmbezztHb7dXBU3xXqzpbjZO_vrEPw4YT22-HsIEf-Y_DD3-uTPjkV9_fcQXUp-3OFt6F0MOzd6iz81b9CrTvfJXT6sF-jn5-ttc1tsvt2sm6tNYRmvpoKympKSCMZJJ20LxJGyriQXuU1dEdFaMJJqAKc704KmjEgjQBpdS9DCwQVaL7lt0HfqEP2g470K2qvTRog7pePkbe9UxWsNXJDaWMM045LrWrCys7TsBOcmZ31csg6zGVxr3ThF3T8LfX4y-r3ahT9K1EAzqBzw_iEght-zS5MafLL5j_XowpzUsdvMilLI0nKR2hhSiq57vKYk6khdnairI3W1UM-ed0_f9-j4zxj-AdhPpxg</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2482664223</pqid></control><display><type>article</type><title>Inhibition of iNKT Cells by the HLA-G-ILT2 Checkpoint and Poor Stimulation by HLA-G-Expressing Tolerogenic DC</title><source>PubMed Central</source><creator>Wu, Ching-Lien ; Caumartin, Julien ; Amodio, Giada ; Anna, François ; Loustau, Maria ; Gregori, Silvia ; Langlade-Demoyen, Pierre ; LeMaoult, Joel</creator><creatorcontrib>Wu, Ching-Lien ; Caumartin, Julien ; Amodio, Giada ; Anna, François ; Loustau, Maria ; Gregori, Silvia ; Langlade-Demoyen, Pierre ; LeMaoult, Joel</creatorcontrib><description>Invariant Natural Killer T (iNKT) cells are a small and distinct population of T cells crucial in immunomodulation. After activation by alpha-GalactosylCeramide (αGC), an exogenic glycolipid antigen, iNKT cells can rapidly release cytokines to enhance specific anti-tumor activity. Several human clinical trials on iNKT cell-based anti-cancer are ongoing, however results are not as striking as in murine models. Given that iNKT-based immunotherapies are dependent mainly on antigen-presenting cells (APC), a human tolerogenic molecule with no murine homolog, such as Human Leucocyte Antigen G (HLA-G), could contribute to this discrepancy. HLA-G is a well-known immune checkpoint molecule involved in fetal-maternal tolerance and in tumor immune escape. HLA-G exerts its immunomodulatory functions through the interaction with immune inhibitory receptors such as ILT2, differentially expressed on immune cell subsets. We hypothesized that HLA-G might inhibit iNKT function directly or by inducing tolerogenic APC leading to iNKT cell anergy, which could impact the results of current clinical trials. Using an ILT2-transduced murine iNKT cell line and human iNKT cells, we demonstrate that iNKT cells are sensitive to HLA-G, which inhibits their cytokine secretion. Furthermore, human HLA-G dendritic cells, called DC-10, failed at inducing iNKT cell activation compared to their autologous HLA-G DCs counterparts. Our data show for the first time that the HLA-G/ILT2 ICP is involved in iNKT cell function modulation.</description><identifier>ISSN: 1664-3224</identifier><identifier>EISSN: 1664-3224</identifier><identifier>DOI: 10.3389/fimmu.2020.608614</identifier><identifier>PMID: 33505397</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>Human Leucocyte Antigen G ; ILT2/CD85j/LILRB1 ; immune regulation ; Immunology ; Natural Killer T cells ; tolerogenic dendritic cells</subject><ispartof>Frontiers in immunology, 2021-01, Vol.11, p.608614-608614</ispartof><rights>Copyright © 2021 Wu, Caumartin, Amodio, Anna, Loustau, Gregori, Langlade-Demoyen and LeMaoult.</rights><rights>Copyright © 2021 Wu, Caumartin, Amodio, Anna, Loustau, Gregori, Langlade-Demoyen and LeMaoult 2021 Wu, Caumartin, Amodio, Anna, Loustau, Gregori, Langlade-Demoyen and LeMaoult</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c465t-24820107460f9cd30e0185967861a507dc3b92a33eafbd3a2409b739ba893a7e3</citedby><cites>FETCH-LOGICAL-c465t-24820107460f9cd30e0185967861a507dc3b92a33eafbd3a2409b739ba893a7e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7832389/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7832389/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33505397$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wu, Ching-Lien</creatorcontrib><creatorcontrib>Caumartin, Julien</creatorcontrib><creatorcontrib>Amodio, Giada</creatorcontrib><creatorcontrib>Anna, François</creatorcontrib><creatorcontrib>Loustau, Maria</creatorcontrib><creatorcontrib>Gregori, Silvia</creatorcontrib><creatorcontrib>Langlade-Demoyen, Pierre</creatorcontrib><creatorcontrib>LeMaoult, Joel</creatorcontrib><title>Inhibition of iNKT Cells by the HLA-G-ILT2 Checkpoint and Poor Stimulation by HLA-G-Expressing Tolerogenic DC</title><title>Frontiers in immunology</title><addtitle>Front Immunol</addtitle><description>Invariant Natural Killer T (iNKT) cells are a small and distinct population of T cells crucial in immunomodulation. After activation by alpha-GalactosylCeramide (αGC), an exogenic glycolipid antigen, iNKT cells can rapidly release cytokines to enhance specific anti-tumor activity. Several human clinical trials on iNKT cell-based anti-cancer are ongoing, however results are not as striking as in murine models. Given that iNKT-based immunotherapies are dependent mainly on antigen-presenting cells (APC), a human tolerogenic molecule with no murine homolog, such as Human Leucocyte Antigen G (HLA-G), could contribute to this discrepancy. HLA-G is a well-known immune checkpoint molecule involved in fetal-maternal tolerance and in tumor immune escape. HLA-G exerts its immunomodulatory functions through the interaction with immune inhibitory receptors such as ILT2, differentially expressed on immune cell subsets. We hypothesized that HLA-G might inhibit iNKT function directly or by inducing tolerogenic APC leading to iNKT cell anergy, which could impact the results of current clinical trials. Using an ILT2-transduced murine iNKT cell line and human iNKT cells, we demonstrate that iNKT cells are sensitive to HLA-G, which inhibits their cytokine secretion. Furthermore, human HLA-G dendritic cells, called DC-10, failed at inducing iNKT cell activation compared to their autologous HLA-G DCs counterparts. Our data show for the first time that the HLA-G/ILT2 ICP is involved in iNKT cell function modulation.</description><subject>Human Leucocyte Antigen G</subject><subject>ILT2/CD85j/LILRB1</subject><subject>immune regulation</subject><subject>Immunology</subject><subject>Natural Killer T cells</subject><subject>tolerogenic dendritic cells</subject><issn>1664-3224</issn><issn>1664-3224</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkVFvFCEUhYnR2Kb2B_hiePRlVobLwPBi0oy13bhRE9dnAgyzS50ZVpgx9t_L7tSm5QFu4JwDlw-htyVZAdTyQ-eHYV5RQsmKk5qX7AU6LzlnBVDKXj6pz9BlSnckDyYBoHqNzvJMKpDiHA3rce-Nn3wYceiw__plixvX9wmbezztHb7dXBU3xXqzpbjZO_vrEPw4YT22-HsIEf-Y_DD3-uTPjkV9_fcQXUp-3OFt6F0MOzd6iz81b9CrTvfJXT6sF-jn5-ttc1tsvt2sm6tNYRmvpoKympKSCMZJJ20LxJGyriQXuU1dEdFaMJJqAKc704KmjEgjQBpdS9DCwQVaL7lt0HfqEP2g470K2qvTRog7pePkbe9UxWsNXJDaWMM045LrWrCys7TsBOcmZ31csg6zGVxr3ThF3T8LfX4y-r3ahT9K1EAzqBzw_iEght-zS5MafLL5j_XowpzUsdvMilLI0nKR2hhSiq57vKYk6khdnairI3W1UM-ed0_f9-j4zxj-AdhPpxg</recordid><startdate>20210111</startdate><enddate>20210111</enddate><creator>Wu, Ching-Lien</creator><creator>Caumartin, Julien</creator><creator>Amodio, Giada</creator><creator>Anna, François</creator><creator>Loustau, Maria</creator><creator>Gregori, Silvia</creator><creator>Langlade-Demoyen, Pierre</creator><creator>LeMaoult, Joel</creator><general>Frontiers Media S.A</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20210111</creationdate><title>Inhibition of iNKT Cells by the HLA-G-ILT2 Checkpoint and Poor Stimulation by HLA-G-Expressing Tolerogenic DC</title><author>Wu, Ching-Lien ; Caumartin, Julien ; Amodio, Giada ; Anna, François ; Loustau, Maria ; Gregori, Silvia ; Langlade-Demoyen, Pierre ; LeMaoult, Joel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c465t-24820107460f9cd30e0185967861a507dc3b92a33eafbd3a2409b739ba893a7e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Human Leucocyte Antigen G</topic><topic>ILT2/CD85j/LILRB1</topic><topic>immune regulation</topic><topic>Immunology</topic><topic>Natural Killer T cells</topic><topic>tolerogenic dendritic cells</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wu, Ching-Lien</creatorcontrib><creatorcontrib>Caumartin, Julien</creatorcontrib><creatorcontrib>Amodio, Giada</creatorcontrib><creatorcontrib>Anna, François</creatorcontrib><creatorcontrib>Loustau, Maria</creatorcontrib><creatorcontrib>Gregori, Silvia</creatorcontrib><creatorcontrib>Langlade-Demoyen, Pierre</creatorcontrib><creatorcontrib>LeMaoult, Joel</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Frontiers in immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wu, Ching-Lien</au><au>Caumartin, Julien</au><au>Amodio, Giada</au><au>Anna, François</au><au>Loustau, Maria</au><au>Gregori, Silvia</au><au>Langlade-Demoyen, Pierre</au><au>LeMaoult, Joel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Inhibition of iNKT Cells by the HLA-G-ILT2 Checkpoint and Poor Stimulation by HLA-G-Expressing Tolerogenic DC</atitle><jtitle>Frontiers in immunology</jtitle><addtitle>Front Immunol</addtitle><date>2021-01-11</date><risdate>2021</risdate><volume>11</volume><spage>608614</spage><epage>608614</epage><pages>608614-608614</pages><issn>1664-3224</issn><eissn>1664-3224</eissn><abstract>Invariant Natural Killer T (iNKT) cells are a small and distinct population of T cells crucial in immunomodulation. After activation by alpha-GalactosylCeramide (αGC), an exogenic glycolipid antigen, iNKT cells can rapidly release cytokines to enhance specific anti-tumor activity. Several human clinical trials on iNKT cell-based anti-cancer are ongoing, however results are not as striking as in murine models. Given that iNKT-based immunotherapies are dependent mainly on antigen-presenting cells (APC), a human tolerogenic molecule with no murine homolog, such as Human Leucocyte Antigen G (HLA-G), could contribute to this discrepancy. HLA-G is a well-known immune checkpoint molecule involved in fetal-maternal tolerance and in tumor immune escape. HLA-G exerts its immunomodulatory functions through the interaction with immune inhibitory receptors such as ILT2, differentially expressed on immune cell subsets. We hypothesized that HLA-G might inhibit iNKT function directly or by inducing tolerogenic APC leading to iNKT cell anergy, which could impact the results of current clinical trials. Using an ILT2-transduced murine iNKT cell line and human iNKT cells, we demonstrate that iNKT cells are sensitive to HLA-G, which inhibits their cytokine secretion. Furthermore, human HLA-G dendritic cells, called DC-10, failed at inducing iNKT cell activation compared to their autologous HLA-G DCs counterparts. Our data show for the first time that the HLA-G/ILT2 ICP is involved in iNKT cell function modulation.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>33505397</pmid><doi>10.3389/fimmu.2020.608614</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1664-3224
ispartof Frontiers in immunology, 2021-01, Vol.11, p.608614-608614
issn 1664-3224
1664-3224
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_568a36708bcb4a4696a8741fc21f766b
source PubMed Central
subjects Human Leucocyte Antigen G
ILT2/CD85j/LILRB1
immune regulation
Immunology
Natural Killer T cells
tolerogenic dendritic cells
title Inhibition of iNKT Cells by the HLA-G-ILT2 Checkpoint and Poor Stimulation by HLA-G-Expressing Tolerogenic DC
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T18%3A02%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Inhibition%20of%20iNKT%20Cells%20by%20the%20HLA-G-ILT2%20Checkpoint%20and%20Poor%20Stimulation%20by%20HLA-G-Expressing%20Tolerogenic%20DC&rft.jtitle=Frontiers%20in%20immunology&rft.au=Wu,%20Ching-Lien&rft.date=2021-01-11&rft.volume=11&rft.spage=608614&rft.epage=608614&rft.pages=608614-608614&rft.issn=1664-3224&rft.eissn=1664-3224&rft_id=info:doi/10.3389/fimmu.2020.608614&rft_dat=%3Cproquest_doaj_%3E2482664223%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c465t-24820107460f9cd30e0185967861a507dc3b92a33eafbd3a2409b739ba893a7e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2482664223&rft_id=info:pmid/33505397&rfr_iscdi=true